Lexicon Pharmaceuticals (NASDAQ:LXRX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Monday, February 4th.
A number of other analysts have also commented on LXRX. Citigroup cut their price target on Lexicon Pharmaceuticals from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, November 2nd. Cowen reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday, November 2nd. BidaskClub raised Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 6th. Gabelli reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday, November 2nd. Finally, Zacks Investment Research downgraded Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 7th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $19.88.
LXRX stock opened at $6.81 on Monday. The stock has a market cap of $721.38 million, a price-to-earnings ratio of -5.36 and a beta of 0.63. Lexicon Pharmaceuticals has a 1-year low of $4.26 and a 1-year high of $13.97.
Several hedge funds have recently modified their holdings of the stock. CWM Advisors LLC boosted its stake in shares of Lexicon Pharmaceuticals by 30.2% in the fourth quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 3,030 shares during the period. Metropolitan Life Insurance Co. NY boosted its stake in shares of Lexicon Pharmaceuticals by 409.3% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 11,862 shares during the period. Paloma Partners Management Co bought a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter valued at approximately $73,000. Squarepoint Ops LLC bought a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter valued at approximately $173,000. Finally, D. E. Shaw & Co. Inc. lifted its stake in Lexicon Pharmaceuticals by 181.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 268,476 shares of the biopharmaceutical company’s stock worth $1,783,000 after purchasing an additional 173,096 shares during the last quarter.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Recommended Story: What is Cost of Debt?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.